This consensus was developed by the Orthodontic Society of the Chinese Stomatological Association to provide a systematic, scientific, and practical guideline for informed consent in orthodontic care. Orthodontic treatment is typically lengthy, highly individualized, and involves multiple factors such as growth and development, occlusal function, and facial esthetics. Rapid technological advances and diverse risk profiles make the traditional reliance on orthodontist experience or institutional templates insufficient to ensure patients′ full understanding and autonomous decision-making. To address this, the expert panel conducted extensive reviews of domestic and international guidelines, analyzed representative dispute cases, and performed multicenter patient-clinician surveys. Using a multi-round Delphi method, the group established a standardized informed consent framework covering the initial consultation, treatment, and retention phases. The consensus emphasizes that informed consent is not only a fundamental legal and ethical requirement but also a key step in building trust, improving patient compliance, and enhancing treatment satisfaction. Orthodontists should clearly and comprehensively explain treatment plans, potential risks, uncertainties, and associated costs, while respecting the autonomy of patients or guardians, and maintain continuous communication and dynamic evaluation throughout the treatment process. The release of this consensus provides unified and authoritative guidance for clinical orthodontics, helping to standardize informed consent, enhance its transparency, safeguard patient rights, reduce medical risks, and promote high-quality, sustainable development of orthodontic practice.

OBJECTIVE: To explore the incidence, clinical features, genetic variant characteristics and prognosis of Glutaric acidemia type I (GA1) among neonates from Henan Province. METHODS: A total of 814 625 neonates undergoing screening for inherited metabolic diseases by tandem mass spectrometry (MS/MS) at the Third Affiliated Hospital of Zhengzhou University from January 2016 to December 2022 were selected as the study subjects. A retrospective method was adopted to collect the clinical data of the patients. Whole exome sequencing was carried out to detect GCDH gene variants in individuals with positive results by GA1 newborn screening, and Sanger sequencing was used to verify the candidate variants. Based on the guidelines from the American College of Medical Genetics and Genomics (ACMG), the pathogenicity of candidate variants was rated. This study was approved by the Medical Ethics Committee of the Hospital (Ethics Number: 2019 Medical Ethics Review No. 67). RESULTS: Eight cases of GA1 were diagnosed among the 814 625 neonates. Blood glutaryl carnitine (C5DC) and urine glutaric acid (GA) levels of the 8 children were higher than the normal reference values. In total 12 variants were detected, all of which were missense variants. c.1064G>A (p.Arg355His) was the most common one, accounting for 21.4% (3/14). Three GCDH gene variants, including 1297G>C (p.Ala433Pro), c.467G>A (p.Gly156Asp) and c.1125T>G (p.Cys375Trp), were previously unreported. REVEL software analysis predicted that all of the three variants were harmful. 3D protein structure modeling indicated that the three variants may cause amino acid residue alterations, and c.1297G>C (p.Ala433Pro) and c.1125T>G (p.Cys375Trp) may result in increase in hydrogen bonds and affect the function of GCDH protein. By December 2023, one of the eight children had deceased, and another child had severe clinical symptoms with poor prognosis. Six children had a good prognosis, of which two had mild motor development delay and four had normal development without clinical symptoms. CONCLUSION The incidence of GA1 in newborns screened by MS/MS in Henan Province is 1/101 828, and the carrier rate of pathogenic GCDH variants is 1/160. The c.1064G>A (p.Arg355His) may be the hotspot variant of the GCDH gene among children with GA1 in Henan. Discovery of the three novel variants has enriched the mutational spectrum of the GCDH gene and provide a basis for the early diagnosis, treatment, prognosis and genetic counseling of this disease.
Humans ; Amino Acid Metabolism, Inborn Errors/epidemiology* ; Glutaryl-CoA Dehydrogenase/chemistry* ; Infant, Newborn ; Female ; Neonatal Screening/methods* ; Male ; Brain Diseases, Metabolic/epidemiology* ; China/epidemiology* ; Retrospective Studies ; Mutation ; Genetic Variation ; Glutarates

Objective:To evaluate the clinical efficacy of endoscopic-assisted dual-plane augmentation mammoplasty via abdominoplasty incision.Methods:The clinical data of patients who underwent concurrent abdominoplasty and endoscopic breast augmentation utilizing a single incision at Xi’an International Medical Center Hospital from August 2023 to February 2024 were retrospectively analyzed. Through a lower abdominal incision, a 4 cm-wide subcutaneous tunnel was endoscopically dissected in a superolateral direction from the lateral aspect of the xiphoid region, traversing the abdominal wall flap dissection area. Initially, the medial-inferior origin of the pectoralis major muscle was exposed and excised. Subsequently, the posterior space of the pectoralis major muscle was dissected to create the prosthesis space, and the rib origin of the pectoralis major muscle was severed 1 cm above the inframammary fold to establish a type Ⅰ dual-plane configuration. Depending on the patients’ breast morphology, the glandular tissue could be dissected superiorly from the surface of the pectoralis major muscle to form a type Ⅱ or type Ⅲ dual-plane. The prosthesis was then implanted, and its position was adjusted accordingly. After the drainage was placed, the remaining operation of abdominoplasty was continued. Patients’ basic information, implant volume, postoperative extubation time, and postoperative complications were recorded. A Likert scale of five points was used to evaluate preoperative and postoperative breast satisfaction [ranges from 1 to 5 points, 1 = very dissatisfied, 2 = dissatisfied, 3 = average, 4 = satisfied, 5 = very satisfied, respectively, satisfaction rate calculated as: ( "very satisfied" + "satisfied" )cases/total cases×100%]. SPSS 25.0 statistical software was used for statistical analysis. Measurement data in accordance with normal distribution were expressed as Mean±SD, and satisfaction scores not in accordance with normal distribution were expressed as M( Q1, Q3), compared by Wilcoxon rank sum test before and after operation. The count data were expressed by cases (%). Results:A cohort of 25 patients were included in the study, with a mean age of (29.8±2.9) years and a mean body mass index (BMI) of (20.8±1.7) kg/m 2. The median volume of the implanted prosthesis was (290.4±40.8) ml (range: 250-410 ml), and the mean extubation time was (3.1±0.9) d (range: 2-6 d). The mean follow-up duration was (270.0±52.4) d (range: 188-356 d). All patients demonstrated full, symmetrical, and natural breast contours. No significant complications, such as infection, hematoma, abnormal breast morphology, implant displacement, or exposure, were observed. The patient satisfaction scores significantly improved from preoperative median 1 (1, 2) to postoperative median 5 (4, 5), and the difference was statistically significant ( Z=-4.44, P<0.001). Patient satisfaction rate increased significantly from 12% (3/25) to 100% (25/25). Conclusion:Endoscopic-assisted dual-plane augmentation mammoplasty via abdominoplasty incision is a straightforward, feasible, safe, and effective procedure that eliminates breast scarring. Postoperative outcomes indicate an absence of serious complications, and patient satisfaction rates are high.

Objective:To explore the incidence, clinical features, genetic variant characteristics and prognosis of Glutaric acidemia type I (GA1) among neonates from Henan Province.Methods:A total of 814 625 neonates undergoing screening for inherited metabolic diseases by tandem mass spectrometry (MS/MS) at the Third Affiliated Hospital of Zhengzhou University from January 2016 to December 2022 were selected as the study subjects. A retrospective method was adopted to collect the clinical data of the patients. Whole exome sequencing was carried out to detect GCDH gene variants in individuals with positive results by GA1 newborn screening, and Sanger sequencing was used to verify the candidate variants. Based on the guidelines from the American College of Medical Genetics and Genomics (ACMG), the pathogenicity of candidate variants was rated. This study was approved by the Medical Ethics Committee of the Hospital (Approval Number: 2019 Medical Ethics Review No. 67). Results:Eight cases of GA1 were diagnosed among the 814 625 neonates. Blood glutaryl carnitine (C5DC) and urine glutaric acid (GA) levels of the 8 children were higher than the normal reference values. In total 12 variants were detected, all of which were missense variants. c. 1064G>A (p.Arg355His) was the most common one, accounting for 21.4% (3/14). Three GCDH gene variants, including 1297G>C (p.Ala433Pro), c. 467G>A (p.Gly156Asp) and c. 1125T>G (p.Cys375Trp), were previously unreported. REVEL software analysis predicted that all of the three variants were harmful. 3D protein structure modeling indicated that the three variants may cause amino acid residue alterations, and c. 1297G>C (p.Ala433Pro) and c. 1125T>G (p.Cys375Trp) may result in increase in hydrogen bonds and may affect the function of GCDH protein. By December 2023, one of the eight children had deceased, and another child had severe clinical symptoms with poor prognosis. Six children had a good prognosis, of which two had mild motor development delay and four had normal development without clinical symptoms. Conclusion:The incidence of GA1 in newborns screened by MS/MS in Henan Province is 1/101 828, and the carrier rate of pathogenic GCDH variants is 1/160. The c. 1064G>A (p.Arg355His) may be the hotspot variant of the GCDH gene among children with GA1 in Henan. Discovery of the three novel variants has enriched the mutational spectrum of the GCDH gene and provide a basis for the early diagnosis, treatment, prognosis and genetic counseling of this disease.

This consensus was developed by the Orthodontic Society of the Chinese Stomatological Association to provide a systematic, scientific, and practical guideline for informed consent in orthodontic care. Orthodontic treatment is typically lengthy, highly individualized, and involves multiple factors such as growth and development, occlusal function, and facial esthetics. Rapid technological advances and diverse risk profiles make the traditional reliance on orthodontist experience or institutional templates insufficient to ensure patients′ full understanding and autonomous decision-making. To address this, the expert panel conducted extensive reviews of domestic and international guidelines, analyzed representative dispute cases, and performed multicenter patient-clinician surveys. Using a multi-round Delphi method, the group established a standardized informed consent framework covering the initial consultation, treatment, and retention phases. The consensus emphasizes that informed consent is not only a fundamental legal and ethical requirement but also a key step in building trust, improving patient compliance, and enhancing treatment satisfaction. Orthodontists should clearly and comprehensively explain treatment plans, potential risks, uncertainties, and associated costs, while respecting the autonomy of patients or guardians, and maintain continuous communication and dynamic evaluation throughout the treatment process. The release of this consensus provides unified and authoritative guidance for clinical orthodontics, helping to standardize informed consent, enhance its transparency, safeguard patient rights, reduce medical risks, and promote high-quality, sustainable development of orthodontic practice.

Hearing loss is the most prevalent disabling disease. Cochlear implantation（CI） serves as the primary intervention for severe to profound hearing loss. This consensus systematically explores the value of genetic diagnosis in the pre-operative assessment and efficacy prognosis for CI. Drawing upon domestic and international research and clinical experience, it proposes an evidence-based medicine three-tiered prognostic classification system（Favorable, Marginal, Poor）. The consensus focuses on common hereditary non-syndromic hearing loss（such as that caused by mutations in genes like GJB2, SLC26A4, OTOF, LOXHD1） and syndromic hereditary hearing loss（such as Jervell & Lange-Nielsen syndrome and Waardenburg syndrome）, which are closely associated with congenital hearing loss, analyzing the impact of their pathological mechanisms on CI outcomes. The consensus provides recommendations based on multiple round of expert discussion and voting. It emphasizes that genetic diagnosis can optimize patient selection, predict prognosis, guide post-operative rehabilitation, offer stratified management strategies for patients with different genotypes, and advance the application of precision medicine in the field of CI.
Humans ; Cochlear Implantation ; Prognosis ; Hearing Loss/surgery* ; Consensus ; Connexin 26 ; Mutation ; Sulfate Transporters ; Connexins/genetics*

The prevalence of Class III malocclusion varies among different countries and regions. The populations from Southeast Asian countries (Chinese and Malaysian) showed the highest prevalence rate of 15.8%, which can seriously affect oral function, facial appearance, and mental health. As anterior crossbite tends to worsen with growth, early orthodontic treatment can harness growth potential to normalize maxillofacial development or reduce skeletal malformation severity, thereby reducing the difficulty and shortening the treatment cycle of later-stage treatment. This is beneficial for the physical and mental growth of children. Therefore, early orthodontic treatment for Class III malocclusion is particularly important. Determining the optimal timing for early orthodontic treatment requires a comprehensive assessment of clinical manifestations, dental age, and skeletal age, and can lead to better results with less effort. Currently, standardized treatment guidelines for early orthodontic treatment of Class III malocclusion are lacking. This review provides a comprehensive summary of the etiology, clinical manifestations, classification, and early orthodontic techniques for Class III malocclusion, along with systematic discussions on selecting early treatment plans. The purpose of this expert consensus is to standardize clinical practices and improve the treatment outcomes of Class III malocclusion through early orthodontic treatment.
Humans ; Malocclusion, Angle Class III/classification* ; Orthodontics, Corrective/methods* ; Consensus ; Child

Objective:To evaluate the clinical outcome of umbilicoplasty with longitudinal umbilical fixation and provide a basis for constructing an umbilicus that conforms to the aesthetic characteristics of Chinese women.Methods:Patients undergoing umbilicoplasty with longitudinal umbilical fixation between December of 2021 and November of 2023 were retrospectively analyzed at Department of Plastic and Aesthetic Surgery, Xi’an International Medical Center Hospital. All patients underwent abdominoplasty to reshape the abdominal contour and umbilicoplasty with longitudinal umbilical fixation to construct a new umbilical. The preoperative and postoperative body mass index (BMI), waist-hip ratio (waist circumference/hip circumference), umbilical contour, and longitudinal and transverse diameter of the umbilical cord were collected. The patients themselves used a 5-point Likert scale to evaluate the satisfaction of umbilicus (from the four aspects of umbilicus size, shape, position, and overall abdominal coordination and aesthetics), abdominal contour satisfaction rate [satisfaction rate= (very satisfied+ satisfed) patients/(total patients)×100%], and the subjective evaluation of umbilicus scar (very not obvious, not obvious, average, obvious, and very obvious). SPSS 25.0 statistical software was used for statistical analysis. Paired t-test or χ 2 test was used for preoperative and postoperative comparison. P<0.05 was considered statistically significant. Results:A total of 438 female patients were included, aged (33.4±5.5) years, including the pregnancy childbirth patients (428 cases) and weight loss patients (10 cases). The median follow-up time was 216(194, 266) days. Preoperative umbilical appearance mainly for the circle, longitudinal oval, transverse oval and convex. After operation, it was mainly longitudinal oval and circle. Early complications related to the umbilical cord were mainly blood circulation disturbance (8 cases). Long-term umbilical complication was mainly periumbilical scar (6 cases). The BMI [(19.96±2.03)kg/m 2 vs. (20.44±2.18)kg/m 2], waist-hip ratio[(0.78±0.04) vs. (0.88±0.08)], transverse diameter of the umbilicus [(0.68±0.26) cm vs. (1.11±0.44) cm] and longitudinal diameter of the umbilicus[(1.66±0.35) cm vs. (1.29±0.44) cm] after the operation were compared with those before the operation, and the differences were statistically significant ( P<0.01). The number of people satisfied with umbilical position [31.51%(138/438)vs. 97.26%(426/438)], umbilical size[11.19%(49/438)vs. 87.44%(383/438)], umbilical shape[7.76%(34/438)vs. 82.19%(360/438)], overall evaluation[(11.42%(50/438)vs. 86.30%(378/438)] and abdominal contour evaluation [12.79%(56/438)vs. 89.04%(390/438)]increased significantly, and the differences were statistically significant compared with those before operation ( P<0.01). The subjective evaluation of periumbilical scar was very not obvious in 171 cases, not obvious in 163 cases, average in 98 cases, and obvious in 6 cases. Conclusion:Umbilicoplasty with longitudinal umbilical fixation is suitable for Chinese women. The vertical oval umbilical constructed by this surgical method demonstrates appropriate size and position, significantly enhancing the overall abdominal aesthetic effect. The patient satisfaction was high and the postoperative effect was stable.

Aim To investigate the impact of G pro-tein-coupled estrogen receptor 1(GPER1),also known as GPR30 playing a significant role in the nerv-ous system,on neuronal damage and cognitive dysfunc-tion following epileptic seizures.Methods The pro-tein expression levels of GPER1 and the DNA damage marker γ-H2AX in epileptic rats were assessed using Western blot.The hippocampal neuronal damage and apoptosis in pilocarpine-induced epilepsy models were evaluated using Nissl and TUNEL staining techniques,compared with GPER1 knockdown(GPER1-KD)rats with wild-type(WT)controls.The behavioral activi-ties,including memory and spatial learning,were mo-nitored during the chronic phase of epilepsy using the IntelliCage system.Results Compared to the control group,GPER1 protein expression in the cerebral cortex and hippocampus significantly increased 24 hours post-epilepsy onset.In the GPER1-KD+EP group,hipp-ocampal neuronal damage was more severe,with a sig-nificant increase in apoptotic neurons compared to the WT+EP group.The IntelliCage data revealed that during free exploration,nose contact,position learn-ing,and reverse position learning stages in the GPER1-KD+EP group exhibited fewer visits and a higher error rate than in the WT+EP group.Conclu-sions Deficiency in GPER1 impairs memory and spa-tial learning abilities following epilepsy,potentially due to exacerbated neuronal injury,apoptosis,and inflam-mation.GPER1 represents a promising therapeutic tar-get for mitigating post-epileptic nerve damage and cog-nitive impairment.